Pathogenesis of thrombocytopenia in cyanotic congenital heart disease

Michael C Lill1, Joseph K Perloff, John S Child

  • 1The Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Insights

Twenty-five percent of patients with cyanotic congenital heart disease (CCHD) have low platelet counts due to reduced platelet production. This may stem from whole megakaryocytes bypassing the lungs, impacting platelet formation in CCHD patients.

Area of Science:

  • Cardiology
  • Hematology
  • Pathophysiology

Background:

  • A notable percentage of patients with cyanotic congenital heart disease (CCHD) experience thrombocytopenia.
  • The underlying causes and frequency of thrombocytopenia in CCHD remain incompletely understood.

Purpose of the Study:

  • To investigate the prevalence and pathogenesis of thrombocytopenia in patients with CCHD.
  • To explore the relationship between platelet production, megakaryocyte mass, and platelet activation in CCHD.

Main Methods:

  • Assessed platelet counts, reticulated platelet counts, thrombopoietin levels, and markers of disseminated intravascular coagulation and platelet activation in 105 CCHD patients.
  • Compared findings to 20 healthy controls.

Main Results:

  • Twenty-five percent (26/105) of CCHD patients exhibited thrombocytopenia (platelet count <100x10(9)/L), all diagnosed with Eisenmenger syndrome.
  • Reduced platelet production was identified as the cause, despite normal megakaryocyte mass and minimal platelet activation.
  • Hypothesized that right-to-left shunts lead to megakaryocytes bypassing pulmonary maturation, reducing platelet counts.

Conclusions:

  • Thrombocytopenia in CCHD is linked to decreased platelet production, not increased destruction or consumption.
  • Platelet counts in CCHD may exist on a spectrum, from low-normal to overtly thrombocytopenic.
  • The proposed mechanism involves altered megakaryocyte trafficking due to intracardiac shunting.

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...